Prolonged upregulation of the expression of HLA class I antigens and costimulatory molecules on melanoma cells treated with 5-aza-2'-deoxycytidine (5-AZA-CdR)

Journal of Immunotherapy

Volumn 22, Issue 1, 1999, Pages 16-24

  Coral, Sandra ^a   Sigalotti, Luca ^a   Gasparollo, Aldo ^a   Cattarossi, Ilaria ^a   Visintin, Alberto ^a   Cattelan, Alessandro ^a   Altomonte, Maresa ^a   Maio, Michele ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

5 Aza 2' deoxycytidine; HLA class I antigens; ICAM 1; LFA 3; Melanoma; Melanoma associated antigens

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; GAMMA INTERFERON; HLA A1 ANTIGEN; HLA A2 ANTIGEN; HLA ANTIGEN CLASS 1; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MELANOMA ANTIGEN;

ALLELE; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; HLA SYSTEM; HUMAN; HUMAN CELL; MELANOMA CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ALLELES; ANTIGENS, CD58; ANTIGENS, NEOPLASM; AZACITIDINE; BLOTTING, WESTERN; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; MELANOMA; NEOPLASM PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0032920527     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-199901000-00003     Document Type: Article

References (31)

1. Maio M, Parmiani G. Melanoma immunotherapy: new dreams or solid hopes? Immunol Today 1996;17:405-7.
2. Boon T, Van den Eynde BJ, Van der Bruggen P. Antigens recognized by T lymphocytes on human tumors. In: Charron D, ed. Genetic diversity of HLA. Functional and medical implication. Sévres: EDK, 1997:75-9. (Proceedings of the 12th International Histocompatibility Workshop and Conference; vol 2).
3. Boon T, Coulie PG, Van den Eynde B. Tumor antigens recognized by T cells. Immunol Today 1997;18:267-8.
4. Schild H, Rotzschke O, Kalbacher H, Rammensee H-G. Limit of T cell tolerance to self proteins by peptide presentation. Science 1990;247:1587-9.
5. Christinck ER, Luscher MA, Barber BH, Williams DB. Peptide binding to class I MHC on living cells and quantitation of complexes required for CTL lysis. Nature 1991;352:67-70.
6. Townsend A, Bodmer H. Antigen recognition by class I-restricted T lymphocytes. Ann Rev Immunol 1989;7:601-24.
7. Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 1995;16:487-94.
8. Rivoltini L, Barracchini KC, Viggiano V, et al. Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. Cancer Res 1995;55:3149-57.
9. Altomonte M, Gloghini A, Bertola G, et al. Differential expression of cell adhesion molecules CD54/CD11a and CD58/CD2 by human melanoma cells and functional role in their interaction with cytotoxic cells. Cancer Res 1993;53:3343-8.
10. Anichini A, Mortarini R, Supino R, Parmiani G. Human melanoma cells with high susceptibility to cell-mediated lysis can be identified on the basis of ICAM-1 phenotype, VLA profile and invasive ability. Int J Cancer 1990;46:508-15.
11. Labarriere N, Diez E, Pandolfino M-C, et al. Optimal T cell activation by melanoma cells depends on a minimal level of antigen transcription. J Immunol 1997;158:1238-45.
12. Jones PA. DNA methylation errors and cancer. Cancer Res 1996; 56:2463-67.
13. Jones PA. Altering gene expression with 5-azacytidine. Cell 1985; 40:485-6.
14. Makgoba MW, Sanders ME, Ginther-Luce GE, et al. ICAM-1 a ligand for LFA-1-dependent adhesion of B, T and myeloid cells. Nature 1988;331:86-8.
15. Sanchez-Madrid F, Krensky AM, Ware CF, et al. Three distinct antigens associated with human T-lymphocyte-mediated cytolysis: LFA-1, LFA-2 and LFA-3. Proc Natl Acad Sci USA 1982;79: 7489-93.
16. 3 domain. J Immunol 1992;148:3202-9.
17. Tsujisaki M, Sakaguchi K, Igarashi M, Richiardi P, Perosa F, Ferrone S. Fine specificity and idiotype diversity of the murine anti-HLA-A2, A28 monoclonal antibodies CR11-351 and KS1. Transplantation 1988;45:632-9.
18. 2m gene. J Clin Invest 1991;88:282-9.
19. Brasoveanu LI, Altomonte M, Gloghini A, et al. Expression of protectin (CD59) in human melanoma and its functional role in cell-and complement-mediated cytotoxicity. Int J Cancer 1995; 61:548-56.
20. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-5.
21. Chen E, Karr RW, Frost JP, Gonwa TA, Ginder GD. Gamma interferon and 5-azacytidine cause transcriptional elevation of class I major histocompatibility complex gene expression in K562 leukemia cells in the absence of differentiation. Mol Cell Biol 1986; 6:1698-705.
22. Ananthaswamy HN. Regulated expression of tumor-specific and MHC class I antigens in an ultraviolet radiation-induced murine skin cancer. J Invest Dermatol 1988;90:263-6.
23. Elliott BE, Carlow DA, Ivimey L, Arnold M, Hampton N, Bosman P. In situ augmentation of class I major histocompatibility antigen expression on immunogenic variants of a spontaneous murine mammary carcinoma. Cancer Res 1987;47:4915-23.
24. Weber J, Salgaller M, Samid D, et al. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2′-deoxycytidine. Cancer Res 1994;54:1766-71.
25. De Smet C, De Backer O, Faraoni I, Lurquin C, Brasseur F, Boon T. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc Natl Acad Sci USA 1996;93:7149-53.
26. Momparler RL, Bouffard DY, Momparler LF, Dionne J, Belanger K, Ayoub J. Pilot phase I-II study on 5-aza-2′-deoxycytidine (Decitabine) in patients with metastatic lung cancer. Anticancer Drugs 1997;8:358-68.
27. Marchand M, Weynants P, Rankin E, et al. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 1995;63:883-5.
28. Mukherji B, Chakraborty NG, Yamasaki S, et al. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci USA 1995;92:8078-82.
29. Cormier JN, Salgaller ML, Prevette T, et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am 1997;3:37-44.
30. Anichini A, Maccalli C, Mortarini R, Lupetti R, Parmiani G. Cytolytic T cell response to differentiation antigens of the melanocyte lineage. In: Maio M, ed. Immunology of human melanoma. Tumor-host interaction and immunotherapy. Ohmsha, Amsterdam, Oxford, Tokyo, Washington, DC: IOS Press, 1996:139-44.
31. Hu X, Chakraborty NG, Sporn JR, Kurtzman SH, Ergin MT, Mukherji B. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res 1996;56:2479-83.